|
US2016010154A1
|
|
Screening assays for therapeutics for parkinson's disease
|
|
US2013017259A1
|
|
Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
|
|
EP2721145A1
|
|
High through-put screening in skin fibroblasts with an alpha-synuclein triplication
|
|
EP2710041A1
|
|
Assay to determine lrrk2 activity in parkinson's disease
|
|
WO2009152521A2
|
|
Diagnosis of neurodegenerative disorders
|
|
WO2009003147A1
|
|
Methods and compositions for the treatment of neurological disorders
|
|
US2009010894A1
|
|
Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
|
|
EP2322168A1
|
|
Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
|
|
GB201008749D0
|
|
Methods and compositions for reduction of side effects of therapeutic treatments
|
|
US2007214509A1
|
|
Methods and systems for identifying compounds that modulate alpha-synuclein aggregation
|
